TAK 850

Drug Profile

TAK 850

Alternative Names: TAK-850

Latest Information Update: 07 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Takeda
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza virus infections
  • Phase I/II Influenza A virus infections; Influenza B virus infections

Most Recent Events

  • 24 Aug 2016 Takeda withdraws a phase II trial for Influenza virus infections (In adults, In volunteers, Prevention) in Japan (SC) (NCT02713061)
  • 15 Mar 2016 Takeda plans a phase II trial for Influenza virus infections (In adults, In volunteers, Prevention) in Japan (SC) (NCT02713061)
  • 02 Oct 2015 Takeda in-licenses Vero cell technology platform from Nanotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top